Aspects of communication in Alzheimer's disease: Clinical features and treatment options

International Psychogeriatrics

Volumn 25, Issue 6, 2013, Pages 877-885

  Woodward, Michael ^a  

^a HEIDELBERG REPATRIATION HOSPITAL   (Australia)

Author keywords

Alzheimer's disease; cognition; communication; functional communication; language

Indexed keywords

DONEPEZIL; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; CAREGIVER; CAREGIVER BURDEN; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMMUNICATION DISORDER; DISEASE COURSE; FAMILY; FRIEND; HUMAN; HUMAN RELATION; LANGUAGE DISABILITY; REVIEW; SOCIAL INTERACTION; SPEECH THERAPY;

ALZHEIMER DISEASE; ANTIPARKINSON AGENTS; CAREGIVERS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; COMMUNICATION; HUMANS; LANGUAGE; MEMANTINE;

EID: 84876700304     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610213000318     Document Type: Review

References (62)

1. Altmann, L. J. and McClung, J. S. (2008). Effects of semantic impairment on language use in Alzheimer's disease. Seminars in Speech and Language, 29, 18-31.
2. Arkin, S. (2007). Language-enriched exercise plus socialization slows cognitive decline in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 22, 62-77.
3. Bassil, N., Thaipisuttikul, P. and Grossberg, G. T. (2010). Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 11, 1765-1771.
4. Bayles, K. A. and Kim, E. S. (2003). Improving the functioning of individuals with Alzheimer's disease: emergence of behavioral interventions. Journal of Communication Disorders, 36, 327-343.
5. Bayles, K. and Tomoeda, C. K. (1994). Functional Linguistic Communication Inventory (FLCI). Tucson, AZ: Canyonlands.
6. Bayles, K. A., Tomoeda, C. K. and Trosset, M. W. (1992). Relation of linguistic communication abilities of Alzheimer's patients to stage of disease. Brain and Language, 42, 454-472.
7. Birks, J. (2009). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews. doi:10. 1002/14651858. CD005593.
8. Blair, M., Marczinski, C. A., Davis-Faroque, N. and Kertesz, A. (2007). A longitudinal study of language decline in Alzheimer's disease and frontotemporal dementia. Journal of the International Neuropsychological Society, 13, 237-245.
9. Brotons, M. and Koger, S. M. (2000). The impact of music therapy on language functioning in dementia. Journal of Music Therapy, 37, 183-195.
10. Chapman, S. B., Weiner, M. F., Rackley, A., Hynan, L. S. and Zientz, J. (2004). Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil. Journal of Speech, Language, and Hearing Research, 47, 1149-1163.
11. Cosentino, S., Scarmeas, N., Albert, S. M. and Stern, Y. (2006). Verbal fluency predicts mortality in Alzheimer's disease. Cognitive and Behavioral Neurology, 19, 123-129.
12. Cotelli, M. et al. (2011). Improved language performance in Alzheimer disease following brain stimulation. Journal of Neurology, Neurosurgery & Psychiatry, 82, 794-797.
13. de Carvalho, I. A. M. and Mansur, L. L. (2008). Validation of ASHA-FACS functional assessment of communication skills for Alzheimer's disease population. Alzheimer Disease & Associated Disorders, 22, 375-381.
14. de Lira, J. O., Ortiz, K. Z., Campanha, A. C., Bertolucci, P. H. and Minett, T. S. (2011). Microlinguistic aspects of the oral narrative in patients with Alzheimer's disease. International Psychogeriatrics, 23, 404-412.
15. Egan, M., Bérubé, D., Racine, G., Leonard, C. and Rochon, E. (2010). Methods to enhance verbal communication between individuals with Alzheimer's disease and their formal and informal caregivers: a systematic review. International Journal of Alzheimer's Disease, doi:10. 4061/2010/906818.
16. Emre, M., Mecocci, P. and Stender, K. (2008). Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. Journal of Alzheimer's Disease, 14, 193-199.
17. Farlow, M. R., Cummings, J. L., Olin, J. T. and Meng, X. (2010). Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 25, 347-352.
18. Ferris, S. et al. (2009a). Severe impairment battery language scale: a language-assessment tool for Alzheimer's disease patients. Alzheimer's & Dementia, 5, 375-379.
19. Ferris, S. et al. (2009b). Treatment effects of memantine on language in moderate to severe Alzheimer's disease patients. Alzheimer's & Dementia, 5, 369-374.
20. Ferris, S. H. et al. (2011). Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimer's Research & Therapy, 3, 22.
21. Forbes-McKay, K. E. and Venneri, A. (2005). Detecting subtle spontaneous language decline in early Alzheimer's disease with a picture description task. Neurological Sciences, 26, 243-254.
22. Foster, P. S. et al. (2012). Acetylcholinesterase inhibitors reduce spreading activation in dementia. Neuropsychologia, 50, 2093-2099.
23. Frank, E. M. (1994). Effect of Alzheimer's disease on communication function. Journal of the South Carolina Medical Association, 90, 417-423.
24. Frankfort, S. V. et al. (2007). Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Pharmacoepidemiology and Drug Safety, 16, 545-551.
25. Frattali, C. M., Thompson, C. M., Holland, A. L., Wohl, C. B. and Ferketic, M. M. (1995). The FACS of life ASHA facs-a functional outcome measure for adults. ASHA, 37, 40-46.
26. Fromm, D. and Holland, A. L. (1989). Functional communication in Alzheimer's disease. Journal of Speech and Hearing Disorders, 54, 535-540.
27. Georges, J., Jansen, S., Jackson, J., Meyrieux, A., Sadowska, A. and Selmes, M. (2008). Alzheimer's disease in real life-the dementia carer's survey. International Journal of Geriatric Psychiatry, 23, 546-551.
28. Glickstein, J. K. and Neustadt, G. K. (1993). Speech-language interventions in Alzheimer's disease. A functional communication approach. Clinics in Communication Disorders, 3, 15-30.
29. Glosser, G., Wiley, M. J. and Barnoski, E. J. (1998). Gestural communication in Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 20, 1-13.
30. Gonzalez Rothi, L. J. et al. (2009). Errorless practice as a possible adjuvant to donepezil in Alzheimer's disease. Journal of the International Neuropsychological Society, 15, 311-322.
31. Grossberg, G. T., Schmitt, F. A., Meng, X., Tekin, S. and Olin, J. (2010). Reviews: effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias, 25, 627-633.
32. Hendryx-Bedalov, P. M. (2000). Alzheimer's dementia. Coping with communication decline. Journal of Gerontological Nursing, 26, 20-24.
33. Hofbauer, R. K., Tocco, M., Hendrix, S., Graham, S. M. and Perhach, J. L. (2010). Memantine and prevention of worsening in functional communication: post hoc analysis of a randomized, placebo-controlled trial in patients with moderate Alzheimer's disease. Poster presented at the 13th International Conference on Alzheimer's Disease, Honolulu, HI, July 10-15.
34. Hopper, T. (2001). Indirect interventions to facilitate communication in Alzheimer's disease. Seminars in Speech and Language, 22, 305-315.
35. Lovestone, S. and Gauthier, S. (2001). Management of Dementia. London: Martin Dunitz.
36. Mahendra, N. (2001). Direct interventions for improving the performance of individuals with Alzheimer's disease. Seminars in Speech and Language, 22, 291-303.
37. Mahendra, N. and Arkin, S. (2003). Effects of four years of exercise, language, and social interventions on Alzheimer discourse. Journal of Communication Disorders, 36, 395-422.
38. Mecocci, P., Bladstrom, A. and Stender, K. (2009). Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. International Journal of Geriatric Psychiatry, 24, 532-538.
39. Miller, M. L., Tocco, M., Hendrix, S., Hofbauer, R. K., Graham, S. M. and Perhach, J. L. (2010). Memantine and prevention of worsening across multiple domains: post hoc analysis of a randomized, placebo-controlled trial in patients with moderate Alzheimer's disease. Poster presented at the 13th International Conference on Alzheimer's Disease, Honolulu, HI, July 10-15.
40. Orange, J. B. and Ryan, E. B. (2000). Alzheimer's disease and other dementias. Implications for physician communication. Clinics in Geriatric Medicine, 16, 153-173.
41. Phillips, L. J., Reid-Arndt, S. A. and Pak, Y. (2010). Effects of a creative expression intervention on emotions, communication, and quality of life in persons with dementia. Nursing Research, 59, 417-425.
42. Pomara, N., Ott, B. R., Peskind, E. and Resnick, E. M. (2007). Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer's Disease and Associated Disorders, 21, 60-64.
43. Potkins, D. et al. (2003). Language impairment in dementia: impact on symptoms and care needs in residential homes. International Journal of Geriatric Psychiatry, 18, 1002-1006.
44. Powell, J. A., Hale, M. A. and Bayer, A. J. (1995). Symptoms of communication breakdown in dementia: carers' perceptions. European Journal of Disorders of Communication, 30, 65-75.
45. Reisberg, B. et al. (2003). Memantine in moderate-to-severe Alzheimer's disease. The New England Journal of Medicine, 348, 1333-1341.
46. Savundranayagam, M. Y., Hummert, M. L. and Montgomery, R. J. (2005). Investigating the effects of communication problems on caregiver burden. Journals of Gerontology, Series B, 60, S48-S55.
47. Saxton, J., Tariot, P., Tocco, M. and Hofbauer, R. K. (2008). Effects of memantine on language and functional communication in patients with moderate to severe Alzheimer's disease receiving stable doses of donepezil. Poster presented at the 60th Annual Meeting of the American Academy of Neurology, Chicago, USA, April 12-19.
48. Saxton, J., Tocco, M., Hofbauer, R. K. and Graham, S. M. (2009). Effects of memantine on language and functional communication in patients with moderate to severe Alzheimer's disease: a pooled analysis. Poster presented at the 61st Annual Meeting of the American Academy of Neurology, Seattle, WA, April 25-May 2.
49. Saxton, J. et al. (2012). Memantine and functional communication in Alzheimer's disease: results of a 12-week, international, randomized clinical trial. Journal of Alzheimer's Disease, 28, 109-118.
50. Schiaratura, L. T. (2008). Non-verbal communication in Alzheimer's disease. Psychologie & Neuropsychiatrie du Vieillissement, 6, 183-188. [Article in French]
51. Schmitt, F. A. et al. (2002). Measuring cognition in advanced Alzheimer's disease for clinical trials. Journal of Neural Transmission. Supplementa, 135-148.
52. Schmitt, F. A., van Dyck, C. H., Wichems, C. H., Olin, J. T. and Memantine MEM-MD-02 Study Group (2006). Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease & Associated Disorders, 20, 255-262.
53. Schulz, J. B. et al. (2011). Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. Journal of Alzheimer's Disease, 25, 463-475.
54. Tappen, R. M., Williams, C. L., Barry, C. and Disesa, D. (2002). Conversation intervention with Alzheimer's patients: increasing the relevance of communication. Clinical Gerontology, 24, 63-75.
55. Tariot, P. N. et al. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 291, 317-324.
56. Tocco, M. and Graham, S. M. (2010). Effects of memantine treatment on language abilities and functional communication in patients with moderate Alzheimer's disease: a review of data. Poster presented at the 13th International Conference on Alzheimer's Disease, July 10-15, Honolulu, HI.
57. Visch Brink, E. G., Van Rhee Temme, W., Rietveld, T., Krulder, J. W., Van Harskamp, F. and Van der Cammen, T. J. (2009). Improvement of spontaneous speech in early stage Alzheimer's with rivastigmine. Journal of Nutrition Health and Aging, 13, 34-38.
58. Weiner, M. F., Neubecker, K. E., Bret, M. E. and Hynan, L. S. (2008). Language in Alzheimer's disease. Journal of Clinical Psychiatry, 69, 1223-1227.
59. Weintraub, D., Somogyi, M. and Meng, X. (2011). Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. American Journal of Alzheimer's Disease and Other Dementias, 26, 443-449.
60. Williams, C. L. (2011). What spouse caregivers know about communication in Alzheimer's disease: development of the AD Communication Knowledge Test. Issues in Mental Health Nursing, 32, 28-34.
61. Winblad, B., Jones, R. W., Wirth, Y., Stöffler, A. and Möbius, H. J. (2007). Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders, 24, 20-27.
62. Woodward, M. et al. (2010). Differentiating the frontal variant of Alzheimer's disease. International Journal of Geriatric Psychiatry, 25, 732-738.